<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979520</url>
  </required_header>
  <id_info>
    <org_study_id>YYU1014</org_study_id>
    <nct_id>NCT04979520</nct_id>
  </id_info>
  <brief_title>Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa</brief_title>
  <official_title>A Small Pilot Study to Develop Biomarkers of Weekly Brodalumab Administration in Hidradenitis Suppurativa Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and&#xD;
      surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are&#xD;
      lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective&#xD;
      drug for this disease. Weekly dosing achieved superior therapeutic outcomes compared to a&#xD;
      dosing given once in every other week. Brodalumab was safe in both regimens, but blood and&#xD;
      tissue studies to better understand this response are still needed. By performing this small&#xD;
      pilot study and collecting blood and tissue samples from participants treated with Brodalumab&#xD;
      once weekly we would like to better characterize the molecular response to this treatment,&#xD;
      identify blood and tissue markers reflecting disease severity, and better understand disease&#xD;
      mechanisms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin-17 receptor A (IL-17RA) saturation during brodalumab administration at week 12 vs baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage change in saturation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in levels of IL-17A, IL-17C, IL-17, CXCL1, and CXCL8</measure>
    <time_frame>12 weeks</time_frame>
    <description>In Brodalumab treated participants at week 12 compared with baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate IL-17R saturation (measured by the frequencies of immune cells positive to IL-17RA by flow cytometry) with clinical measures, such as pain or the Hidradenitis Suppurativa Severity Score System (IHS4)</measure>
    <time_frame>12 weeks</time_frame>
    <description>In Brodalumab treated participants at week 12 compared with baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <condition>Acne Inversa</condition>
  <arm_group>
    <arm_group_label>Brodalumab treated moderate-to-severe HS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly Brodalumab treatment 210mg/1.5ml, given subcutaneously for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brodalumab</intervention_name>
    <description>Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week</description>
    <arm_group_label>Brodalumab treated moderate-to-severe HS patients</arm_group_label>
    <other_name>Siliq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed clinical diagnosis of Hidradenitis Suppurativa by the Principal Investigator&#xD;
&#xD;
          -  Age 18 to 99 years old&#xD;
&#xD;
          -  Moderate to severe Hidradenitis Suppurativa with draining tunnels (Hidradenitis&#xD;
             Suppurativa Severity Score System/IHS4&gt;4)&#xD;
&#xD;
          -  Must have medical insurance that is willing to pay for the study drug throughout the&#xD;
             duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory Bowel Disease&#xD;
&#xD;
          -  HIV Positive&#xD;
&#xD;
          -  Active Hepatitis B or C Infection&#xD;
&#xD;
          -  Pregnant or Breastfeeding&#xD;
&#xD;
          -  No concurrent use of any systemic antibiotics/retinoids/immunosuppressants/biologics&#xD;
             (require washout period of &gt;5 half-lives)&#xD;
&#xD;
          -  A Score of &gt;10 on the Beck's Depression Inventory (BDI) or on the Patient Health&#xD;
             Questionnaire (PHQ)-9&#xD;
&#xD;
          -  History of Keloid Scarring&#xD;
&#xD;
          -  Any medical, psychological or social condition that, in the opinion of the&#xD;
             Investigator, would jeopardize the health or well-being of the participant during any&#xD;
             study procedures or the integrity of the data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yael Renert-Yuval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rockefeller University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Office</last_name>
    <phone>18007822737</phone>
    <email>rucares@rockefeller.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yael Renert-Yuval, MD</last_name>
    <phone>2123277581</phone>
    <email>yrenert@rockefeller.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yael Renert-Yuval, MD</last_name>
      <phone>212-327-7581</phone>
      <email>yrenert@rockefeller.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rockefeller University</investigator_affiliation>
    <investigator_full_name>Yael Renert-Yuval</investigator_full_name>
    <investigator_title>Instructor in clinical investigation</investigator_title>
  </responsible_party>
  <keyword>Hidradenitis Suppurativa</keyword>
  <keyword>Acne Inversa</keyword>
  <keyword>Brodalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brodalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

